Elsevier has launched Embase AI, a generative AI-powered version of its leading biomedical literature database, Embase, on June 25, 2025. This innovative solution transforms how researchers, medical professionals, and educators access and analyze biomedical data by introducing natural language search and summarization capabilities, enhancing efficiency and accessibility across diverse teams.
Embase AI addresses the challenge of navigating vast biomedical literature by allowing users to query in natural language, making insights accessible without requiring technical expertise. “Embase AI is changing the way researchers and other users go about solving problems and helps them save valuable time searching for answers, digesting information, and avoiding the risk of missing valuable insights,” said Mirit Eldor, Managing Director, Life Sciences, Elsevier. The platform delivers instant, natural language summaries with fully referenced sources, reducing research time and enhancing decision-making confidence.
Built on Embase’s trusted database, which includes 45.7 million records from over 8,500 journals (3,365 unique to Embase) and 5.1 million conference abstracts, Embase AI searches in real time to provide up-to-date results. Its two-stage ranking system and Emtree thesaurus, with over 99,730 preferred terms and 525,755 synonyms, ensure precision and explainability.
Developed in alignment with Elsevier’s Responsible AI and Privacy Principles, Embase AI prioritizes data security. Third-party large language models (LLMs) are used privately, with no data stored or used to train public models, and all information is housed in a secure, Elsevier-exclusive environment. This commitment ensures compliance with regulations like GDPR and supports applications in pharmacovigilance and systematic reviews, recognized by regulatory bodies such as the European Commission and NICE.
Embase AI aligns with the growing demand for AI-driven tools in biomedical research, as evidenced by innovations like PubTator 3.0, which enhances literature search with AI-powered entity recognition. Unlike PubTator, which focuses on PubMed and PMC, Embase AI’s broader scope includes unique content not in MEDLINE, making it a critical resource for comprehensive literature reviews. The platform’s integration with tools like the PICO method and Emtree indexing further streamlines evidence-based medicine practices, supporting researchers in academia, life sciences, and regulatory affairs.
Embase AI positions Elsevier as a leader in responsible AI innovation, empowering users to uncover critical insights efficiently while maintaining trust and accuracy. To explore Embase AI, users can request a demo or access it via Elsevier’s subscription plans.
A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.